Advancing Drug Development and Disease Modeling with Human iPSC-derived Organoids

At ACROBiosystems, Idil Ariöz has played a crucial role in providing support and guidance to customers, as well as developing promotion and co-marketing strategies by analyzing industry pain-points. Before joining ACROBiosystems, Idil conducted academic scientific research in various fields of neuroscience during her master's and doctoral studies. Her research focused on topics such as neural regeneration, spatial distribution of synaptic proteins at the nano-scale, and molecular targets in epileptogenic neurodevelopmental diseases.
In snapshot:
· Organoids represent promising advancements in translatable disease modeling and overcoming the high preclinical drug failure rate.
· ACROBiosystems offers hydrogel-free human iPSC-derived organoids, which are miniature organs composed of multiple cell types. These organoids include inherent vascular and immune components and have been verified through multi-modal functional and structural tests. The available organoid types are:
- Cardiac organoids
- Cerebral organoids
- Liver organoids
- Intestinal organoids
· These organoids have been used to create disease models of Alzheimer’s Disease, Parkinsons’s Disease, Nonalcoholic Fatty Liver Disease (NASH), Inflammatory Bowel Disease (IBD), acute toxicity, neuroinflammation and have been used as AAV gene delivery models.
· ACROBiosystems hiPSC-derived organoids may be promising improved preclinical models for drug development, safety assessment and diseases models to help provide better guidance when moving into clinical research.
If you're interested in ACROBiosystems' Organoid Solutions, fill out the organoid questionnaire here to win a llama plush: bit.ly/3x1roal